한글목차

이 보고서는 TNF 억제제, Entyvio, Stelara, Skyrizi, Rinvoq, Tremfya, Omvoh, Zeposia, Velsipity와 같은 크론 병에 대한 현재 및 새로운 치료법을 탐구합니다. 이러한 치료제의 효능, 안전성 및 유용성을 자세히 분석하고 향후 처방 동향을 형성할 수 있는 최근의 임상시험에 대한 통찰력도 제공합니다. 바이오시밀러와 피하주제제가 시장에 미치는 영향을 검증하고 중등도에서 중증의 크론병의 치료상황이 어떻게 진화하고 있는지를 상세하게 고찰했습니다.

목차

주요 요약

조사 목적

• 가미시 끝난 약
  • TNF 억제제(Remicade, Humira, Cimzia)
  • Entyvio(베드리주맙, Takeda)
  • Stelara(우스테키누맙, Johnson & Johnson)
  • Skyrizi(리산키주맙;AbbVie)
  • Rinvoq(유파다시티닙, AbbVie)
• 파이프라인 의약품제
  • Tremfya(구세르크맙, Johnson & Johnson Biotech)
  • Omvoh(밀리키주맙, Lilly)
  • Zeposia(오자니모드, Bristol Myers Squibb)
  • Velsipity(에트라시모드, Pfizer)

미래의 치료 동향

• 크론병의 장래의 치료 전략은 병용 요법, IL-23 억제제, 경구 요법이 유리하게 될 가능성이 있다
  • FMT는 CD에 응용할 수 있을 가능성이 있지만, 그 전략은 복잡하고, 지금까지 실증되어 있지 않다

부록

영문목차

Explore current and emerging treatments for Crohn's disease, including TNF inhibitors, Entyvio, Stelara, Skyrizi, Rinvoq, Tremfya, Omvoh, Zeposia, and Velsipity. This comprehensive report offers an in-depth analysis of the efficacy, safety, and usability of these treatments, as well as insights into recent clinical trials that could shape future prescribing trends. Examine the impact of biosimilars and subcutaneous formulations on the market, offering a detailed look at how the treatment landscape for moderate-to-severe Crohn's disease is evolving. Gain valuable knowledge on physician and payer preferences, the competitive positioning of pipeline products, and the overall market trends influencing drug therapies for Crohn's disease.

Key brands covered in this report:

• Remicade (infliximab)
• Humira (adalimumab)
• Cimzia (certolizumab pegol)
• Entyvio (vedolizumab)
• Stelara (ustekinumab)
• Skyrizi (risankizumab)
• Rinvoq (upadacitinib)
• Tremfya (guselkumab)
• Omvoh (mirikizumab)
• Zeposia (ozanimod)
• Velsipity (etrasimod)

Key questions answered:

• Which CD therapies are preferred for different patient segments and lines of therapy?
• How do medical professionals perceive the efficacy, tolerability, and ease of administration of these therapies?
• Which recent clinical trials could significantly influence CD prescribing trends?
• How might the use of current and pipeline drugs change in the future?
• What must pipeline products demonstrate to compete with existing CD therapies?
• Which pipeline products are most promising and how might they impact the market?
• How will the CD treatment landscape evolve for different patient segments and therapy lines?

Companies:

AbbVie, Lilly, AstraZeneca, UCB, Pfizer, Merck Sharp & Dohme, Bristol Myers Squibb, Takeda, Johnson & Johnson.

Table of Contents

Executive summary

Research objectives

• Marketed drugs
  • TNF inhibitors (Remicade, Humira, Cimzia)
  • Entyvio (vedolizumab; Takeda)
  • Stelara (ustekinumab; Johnson & Johnson)
  • Skyrizi (risankizumab; AbbVie)
  • Rinvoq (upadacitinib; AbbVie)
• Pipeline drugs
  • Tremfya (guselkumab; Johnson & Johnson Biotech)
  • Omvoh (mirikizumab; Lilly)
  • Zeposia (ozanimod; Bristol Myers Squibb)
  • Velsipity (etrasimod; Pfizer)

Future treatment trends

• Future treatment strategies for Crohn's could favour combinations, IL-23 inhibitors and oral therapies
  • FMT could have some applications in CD, but the strategy is complex and, to date, unproven

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe